Driven by insulin pens, inhalers, vials and prefillable syringes
Gerresheimer saw revenues increase by 4% at constant exchange rates to 1.02bn in the financial year 2010 (1 December 2009 to 30 November 2010).
The main contributors to this growth in the pharmaceuticals business for the German supplier of glass and plastic packaging were insulin pens, inhalers, vials, ampoules and prefillable syringes. The market for life science research products also recovered.
Gerresheimer increased its adjusted EBITDA to 204.5m in 2010, up 10% on the previous year.
Net income reached a record level of 46.7m (7.0m in 2009).
Gerresheimer chief executive Uwe R๖hrhoff said: In 2010 we achieved our targets and even exceeded some of them.
In the coming years he said the firm wanted to become a full service provider, particularly in growth markets such as diabetes and generics.
He added that the firm aims by 2013 to double revenue in emerging markets to 200m.
In 2011, Gerresheimer expects revenue growth of 34% at constant exchange rates.
The Gerresheimer Group has production operations at 44 sites in Europe, North and South America and Asia. It employs around 9,500 people.